Phase 0 lead-in trial of Pitavastatin in primary and recurrent Glioblastoma patients

2023-505743-38-00 Protocol 10227 Human pharmacology (Phase I) - Other Ended

Start 18 Jan 2024 · End 19 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 10227

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 18
Countries 1
Sites 1

Glioblastoma Multiforme

Key facts

Sponsor
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04], Diseases [C] - Nervous System Diseases [C10]
Trial duration
18 Jan 2024 → 19 Jul 2024
Decision date (initial)
2023-10-16
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2023-505743-38-00
WHO UTN
U1111-1294-4392

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glioblastoma Multiforme

VersionLevelCodeTermSystem organ class
20.0 PT 10018337 Glioblastoma multiforme 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Sponsor organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Address
Dr. Molewaterplein 40
City
Rotterdam
Postcode
3015 GD
Country
Netherlands

Scientific contact point

Organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Contact name
P. Achaiber Sing

Public contact point

Organisation
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Contact name
P. Achaiber Sing

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 18 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neurosurgery, Dr. Molewaterplein 40, 3015 GD, Rotterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-01-18 2024-07-19 2024-01-18 2024-07-09

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-21 Netherlands Acceptable
2023-10-16
2023-10-16